🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalHas anyone dealt with german krankenkasse coverage for glp-1?

Has anyone dealt with german krankenkasse coverage for glp-1?

MarkLI_maint Wed, Sep 10, 2025 at 12:18 PM 19 replies 1,556 viewsPage 1 of 4
This thread is more than 9 months old. Information may be outdated. Consider searching for more recent discussions.
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Sep 10, 2025 at 12:18 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

The bit I cannot resolve on my own is what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
22 17RunnerRach, TrialNerd_Beth, HPLC_Greg and 19 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Sep 10, 2025 at 1:00 PM#2
MarkLI_maint said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
MarkLI_maint said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Sep 10, 2025 at 6:00 PM
21 16pam_stl, wei_SG, cory_ATX and 18 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Sep 10, 2025 at 1:42 PM#3
MarkLI_maint said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

I read this differently from MarkLI_maint, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

20 15sarah_TO, wendy_avl, jason_paloalto and 17 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Sep 10, 2025 at 2:24 PM#4
NeuroNate said:
The affordability discussion here usually stops at individual tactics.

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

  1. Prior authorization appeal with peer-to-peer review
  2. Manufacturer copay card (for commercial insurance)
  3. Patient assistance programs (Novo Nordisk, Eli Lilly)
  4. Compounded medication from a 503B pharmacy ($131/month)
  5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

19 14SkepticalSean, Dr.CardioMD, EndoResFellow and 16 others
Reply Quote Save Share Report
HealthEcon_DC
Member
567
3,456
Apr 2024
Washington, DC
Sep 10, 2025 at 6:22 PM#5
Dr.RenalNash said:
MarkLI_maint said: ...my insurance denied cost and coverage coverage because...

Second this. I had assumed I was the exception until I read this.

Last edited: Sep 10, 2025 at 8:22 PM
18 13TrialTracker_MD, JennaRN, LabKate and 15 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register